Professor, Institute of Biochemistry and Cell Biology,
Chinese Academy of Sciences
CEO, Shanghai Health Digit Co., Ltd.
In addition to teaching, Gengxi Hu is founder and CEO of the Shanghai Health Digit Co., Ltd., a company focused on R&D of advanced protein chips for medical applications such as cancer diagnosis.
Dr. Hu worked at the Massachusetts Institute of Technology from 1990 to 1996, first as a postdoctoral fellow in the Division of Toxicology and then in the Center for Environmental Health Sciences as a research scientist. During his research at MIT, Dr. Hu developed an ultra sensitive technology to detect somatic DNA mutations in the restriction reorganization sites of DNA endonucleases from normal human samples. Dr. Hu also systematically identified a set of mitochondria pseudogenes in the human nuclear genome, a significant contribution toward the understanding of exchange among subcellular organelles.
In 1996, Dr. Hu was recruited back to Shanghai and continued his research as leader of a junior group at the Max-Planck Guest Laboratory, jointly supported by the Max-Planck Society of Germany and the Chinese Academy of Sciences in Shanghai.
Dr. Hu serves as vice leader of the Bioinformatics Group of the Chinese 863 Program and as advisor to the Chinese Society of Bioengineering. He has contributed to over a dozen articles published in scientific journals.
Dr. Hu received his bachelor's degree in biology from Hangzhou University and his doctorate from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences.